Abstract:The development of injectable integrin alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonists attracts much attention of research for treating of acute ischemic diseases in recent years. In this work, based on a dataset composed of 102 tricyclic piperazine/piperidine furnished dual alpha(v)beta(3) and alpha(IIb)beta(3) antagonists, a variety of in silico modeling approaches including the comparative molecular field analysis (CoMFA), comparative similarity indices analysis (CoMSIA), and molecular docking were applied to reveal the requisite 3D structural features impacting the biological activities. Our statistical results show that the ligand-based 3D-QSAR models for both the alpha(v)beta(3) and alpha(IIb)beta(3) studies exhibited satisfactory internal and external predictability, i.e., for the CoMFA models, results of Q(2) = 0.48, R-ncv(2) = 0.87, R-pred(2) = 0.71 for alpha(v)beta(3) and Q(2) = 0.50, R-ncv(2) = 0.85, R-pred(2) = 0.72 for alpha(IIb)beta(3) analysis were obtained, and for the CoMSIA ones, the outcomes of Q(2) = 0.55, R-ncv(2) = 0.90, R-pred(2) = 0.72 for alpha(v)beta(3) and Q(2) = 0.52, R-ncv(2) = 0.88, R-pred(2) = 0.74 for alpha(IIb)beta(3) were achieved respectively. In addition, through a comparison between 3D-QSAR contour maps and docking results, it is revealed that that the most crucial interactions occurring between the tricyclic piperazine/piperidine derivatives and alpha(v)beta(3)/alpha(IIb)beta(3) receptor ligand binding pocket are H-bonding, and the key amino acids impacting the interactions are Arg214, Asn215, Ser123, and Lys253 for alpha(v)beta(3), but Arg214, Asn215, Ser123 and Tyr190 for alpha(IIb)beta(3) receptors, respectively. Halogen-containing groups at position 15 and 16, benzene sulfonamide substituent at position 23, and the replacement of piperazine with 4-aminopiperidine of ring B may increase the alpha(v)beta(3)/alpha(IIb)beta(3) antagonistic activity. The potencies for antagonists to inhibit isolated alpha(v)beta(3) and alpha(IIb)beta(3) are linear correlated, indicating that similar interaction mechanisms may exist for the series of molecules. To our best knowledge this is the first report on 3D-QSAR modeling of these dual alpha(v)beta(3)/alpha(IIb)beta(3) antagonists. The results obtained should provide information for better understanding of the mechanism of antagonism and thus be helpful in design of novel potent dual alpha(v)beta(3)/alpha(IIb)beta(3) antagonists. (C) 2011 Elsevier Inc. All rights reserved.

Binding Investigation of Integrin Αvβ3 with Its Inhibitors by SPR Technology and Molecular Docking Simulation

2D-QSAR studies of integrin αvβ3 antagonists

Studies of Tricyclic Piperazine/piperidine Furnished Molecules As Novel Integrin Αvβ3/αiibβ3 Dual Antagonists Using 3D-QSAR and Molecular Docking.

The application of computer aided drug design in the development of integrin αvβ3 ligands

Novel Linear Peptides with High Affinity to Αvβ3 Integrin for Precise Tumor Identification.

Computational Design of Peptide-Au Cluster Probe for Sensitive Detection of Α(iib)β3 Integrin.

Investigations of FAK Inhibitors: a Combination of 3D-QSAR, Docking, and Molecular Dynamics Simulations Studies.

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Study of properties of VEGFR2 active site and binding mode of VEGFR2 and its inhibitors

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

Correlation Between Biological Activity and Binding Energy in Systems of Integrin with Cyclic Rgd-Containing Binders: A Qm/Mm Molecular Dynamics Study

The Challenges and Opportunities of Αvβ3-Based Therapeutics in Cancer: from Bench to Clinical Trials

Structural insights into the molecular recognition of integrin αVβ3 by RGD-containing ligands: The role of the specificity-determining loop (SDL)

<i>In silico</i> studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations

A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens

Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives

Biomimetic Design of Platelet Adhesion Inhibitors to Block Integrin Α2β1-Collagen Interactions: II. Inhibitor Library, Screening, and Experimental Validation.

Design and Synthesis of Novel Dual-Cyclic RGD Peptides for Αvβ3 Integrin Targeting.

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

Design of Novel Focal Adhesion Kinase Inhibitors Using 3D-QSAR and Molecular Docking

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8